BECN
BEACON ROOFING SUPPLY INC
No data for this timeframe.
Vol
Inst. Holders9 funds
Inst. Value$1.2B
Inst. Activity0 buys / 8 sells
Recent Activity
Inst.
VANGUARD GROUP INC — EXIT
0 shares ($0.00)
Inst.
FMR LLC — EXIT
0 shares ($0.00)
Analyst Ratings
0Strong Buy
0Buy
4Hold
1Sell
2Strong Sell
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $642.3M | EXIT |
| FMR LLC | $168.5M | EXIT |
| CITADEL ADVISORS LLC | $149.0M | DOUBLED |
| MORGAN STANLEY | $84.9M | EXIT |
| BANK OF AMERICA CORP | $79.8M | EXIT |
9 institutional holders with $1.2B total value (9,930,071 shares) as of 2025-Q1. Top holders: VANGUARD, FMR, CITADEL. Net selling activity: 5 institutions trimmed/exited vs 2 added.
Top Institutional Holders — 2025-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 5,192,734 | $642.3M | 52.3% | EXIT -100.0% |
| 2 | FMR LLC | 1,362,398 | $168.5M | 13.7% | EXIT -100.0% |
| 3 | CITADEL ADVISORS LLC | 1,204,268 | $149.0M | 12.1% | DOUBLED +624.3% |
| 4 | MORGAN STANLEY | 686,497 | $84.9M | 6.9% | EXIT -100.0% |
| 5 | BANK OF AMERICA CORP /DE/ | 644,767 | $79.8M | 6.5% | EXIT -100.0% |
| 6 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 604,984 | $74.8M | 6.1% | EXIT -100.0% |
| 7 | UBS Group AG | 146,918 | $18.2M | 1.5% | EXIT -100.0% |
| 8 | WELLS FARGO & COMPANY/MN | 74,725 | $9.2M | 0.8% | EXIT -100.0% |
| 9 | TWO SIGMA INVESTMENTS, LP | 12,780 | $1.6M | 0.1% | EXIT -100.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | EXIT | 5,192,734 | 0 | -100.0% | $0.00 | 2025-Q2 |
| FMR LLC | EXIT | 1,362,398 | 0 | -100.0% | $0.00 | 2025-Q2 |
| MORGAN STANLEY | EXIT | 686,497 | 0 | -100.0% | $0.00 | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | EXIT | 644,767 | 0 | -100.0% | $0.00 | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | EXIT | 74,725 | 0 | -100.0% | $0.00 | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | EXIT | 604,984 | 0 | -100.0% | $0.00 | 2025-Q2 |
| UBS Group AG | EXIT | 146,918 | 0 | -100.0% | $0.00 | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 12,780 | 0 | -100.0% | $0.00 | 2025-Q2 |
| FMR LLC | TRIM | 4,936,326 | 1,362,398 | -72.4% | $168.5M | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 166,259 | 1,204,268 | +624.3% | $149.0M | 2025-Q1 |
| MORGAN STANLEY | TRIM | 1,138,267 | 686,497 | -39.7% | $84.9M | 2025-Q1 |
| UBS Group AG | ADD | 76,459 | 146,918 | +92.2% | $18.2M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 36,141 | 12,780 | -64.6% | $1.6M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 68,757 | 0 | -100.0% | $0.00 | 2025-Q1 |
| NORGES BANK | EXIT | 931,024 | 0 | -100.0% | $0.00 | 2025-Q1 |
| NORGES BANK | DOUBLED | 365,715 | 931,024 | +154.6% | $94.6M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 223,638 | 68,757 | -69.3% | $7.0M | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 603,748 | — | $52.2M | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 0% buy across 7 analysts — 0 strong buy, 0 buy, 4 hold, 1 sell, 2 strong sell. No current recommendation available.
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Mar 1, 2026 | 0 | 0 | 4 | 1 | 2 | 0% | |
| Feb 1, 2026 | 0 | 0 | 4 | 1 | 2 | 0% | |
| Jan 1, 2026 | 0 | 0 | 4 | 1 | 2 | 0% | |
| Dec 1, 2025 | 0 | 0 | 4 | 1 | 2 | 0% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.